Binod Dhakal

64PUBLICATIONS
203CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (64)

|Jul 20, 2026
Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

|Apr 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Mar 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Feb 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Priyanka Venkatesh, Gayathri Ravi, Binod Dhakal

|Feb 13, 2026
Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance.

Shahram Arsang-Jang, Ben Massat, Gokul Pareek

Pageof 11

Frequent Collaborators

21 joint publications

Anita D'Souza

20 joint publications

Meera Mohan

15 joint publications

Saurabh Chhabra

11 joint publications

Larry D Anderson